Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High
In response to the company posting pleasing third-quarter results and boosting guidance, shares of Halozyme Therapeutics (NASDAQ: HALO), a biotech that focuses on making other drugs more effective, jumped 13% as of 1:45 p.m. EST.
Here's an overview of the headline numbers from the quarter.
The upbeat quarterly results enabled management to make a number of positive changes to its full-year guidance:
Source: Fool.com
Halozyme Therapeutics Inc. Stock
€90.90
-1.260%
With 23 Buy predictions and 1 Sell predictions Halozyme Therapeutics Inc. is one of the favorites of our community.
With a target price of 95 € there is a slightly positive potential of 4.51% for Halozyme Therapeutics Inc. compared to the current price of 90.9 €.
